Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

• Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus

• Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial with SB414

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has completed a transaction with KNOW Bio, LLC granting Novan exclusive worldwide rights for certain oncovirus applications of nitric oxide-based products. An oncovirus is a virus that causes cancer. The agreement allows Novan to expand its viral platform by exploring nitric oxide’s antiviral activity against neoplasias and carcinomas caused by high-risk human papillomavirus (HPV). Novan intends to focus HPV-related development on localized therapies to treat HPV-associated sexually transmitted infections, including pre-cancerous lesions of the cervix and anus.